ATE123498T1 - Glykoprotein menschlichen ursprungs, physiologisch aktiver faktor, der es enthält und heilmittel daraus. - Google Patents

Glykoprotein menschlichen ursprungs, physiologisch aktiver faktor, der es enthält und heilmittel daraus.

Info

Publication number
ATE123498T1
ATE123498T1 AT90904429T AT90904429T ATE123498T1 AT E123498 T1 ATE123498 T1 AT E123498T1 AT 90904429 T AT90904429 T AT 90904429T AT 90904429 T AT90904429 T AT 90904429T AT E123498 T1 ATE123498 T1 AT E123498T1
Authority
AT
Austria
Prior art keywords
glycoprotein
human origin
remedies
physiologically active
active factor
Prior art date
Application number
AT90904429T
Other languages
English (en)
Inventor
Kanji Higashio
Shinjiro Mitsuda
Nobuyuki Shima
Yasuharu Itagaki
Masaya Nagao
Original Assignee
Snow Brand Milk Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26340889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE123498(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd
Application granted granted Critical
Publication of ATE123498T1 publication Critical patent/ATE123498T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT90904429T 1989-03-10 1990-03-09 Glykoprotein menschlichen ursprungs, physiologisch aktiver faktor, der es enthält und heilmittel daraus. ATE123498T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5863189 1989-03-10
JP669290 1990-01-16

Publications (1)

Publication Number Publication Date
ATE123498T1 true ATE123498T1 (de) 1995-06-15

Family

ID=26340889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90904429T ATE123498T1 (de) 1989-03-10 1990-03-09 Glykoprotein menschlichen ursprungs, physiologisch aktiver faktor, der es enthält und heilmittel daraus.

Country Status (17)

Country Link
US (2) US5587359A (de)
EP (1) EP0462277B1 (de)
JP (1) JPH0768272B2 (de)
KR (1) KR960009054B1 (de)
AT (1) ATE123498T1 (de)
AU (1) AU629314B2 (de)
CA (1) CA2049017C (de)
DE (1) DE69019962T2 (de)
DK (1) DK0462277T3 (de)
ES (1) ES2075199T3 (de)
FI (1) FI102681B (de)
HU (2) HU212513B (de)
IE (1) IE64005B1 (de)
NO (1) NO180796C (de)
NZ (1) NZ232813A (de)
RU (1) RU2113480C1 (de)
WO (1) WO1990010651A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
DE69133492T2 (de) * 1990-06-11 2006-08-10 Nakamura, Toshikazu Rekombinanter menschlicher Hepatozytwachstumsfaktor und Verfahren zu seiner Herstellung
DE69131069T2 (de) * 1990-07-13 1999-07-15 Snow Brand Milk Products Co., Ltd., Sapporo, Hokkaido Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung
EP0571387B1 (de) * 1990-09-14 2003-12-17 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Ein nicht-mitogener kompetitiver hgf-antagonist
US5821223A (en) * 1990-09-14 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating cell growth with a novel broad spectrum human lung fibroblast-derived mitogen
JP3200609B2 (ja) * 1990-12-28 2001-08-20 敏一 中村 上皮細胞増殖促進剤
JPH0597A (ja) * 1991-06-21 1993-01-08 Snow Brand Milk Prod Co Ltd 新規抗ｔｃｆ−ｉｉモノクローナル抗体及びそれを用いるｔｃｆ−ｉｉの測定方法
EP0653211B1 (de) * 1992-07-16 2001-10-17 Snow Brand Milk Products Co., Ltd. Normalisierer der blutkoagulation enthaltend tcf-ii als aktiven bestandteil
JP3380573B2 (ja) 1992-07-16 2003-02-24 第一製薬株式会社 Ｔｃｆ−ｉｉを有効成分とする蛋白合成促進剤
KR100271087B1 (en) * 1992-07-16 2000-11-01 Snow Brand Milk Products Co Ltd Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia
JPH07507328A (ja) * 1992-12-28 1995-08-10 雪印乳業株式会社 Ｔｃｆ変異体
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
JP2747979B2 (ja) * 1994-08-19 1998-05-06 雪印乳業株式会社 ヒト由来の糖蛋白質からなる生理活性因子を有効成分とする医薬
ZA9510982B (en) * 1994-12-27 1996-08-22 Snow Brand Milk Products Co Ltd TCF mutant
JPH08176007A (ja) * 1994-12-27 1996-07-09 Snow Brand Milk Prod Co Ltd 脂質代謝異常治療剤
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
AU4027601A (en) * 1995-07-11 2001-07-26 Snow Brand Milk Products Co., Ltd. Lyophilized HGF preparations
JP4006058B2 (ja) 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
ES2274567T3 (es) 1997-03-14 2007-05-16 Daiichi Pharmaceutical Co., Ltd. Utilizacion de tcf-ii para el tratamiento de la perdida de peso corporal, la anemia y la elevacion de tnf causadas por el cancer.
JPH1129493A (ja) * 1997-07-14 1999-02-02 Snow Brand Milk Prod Co Ltd 放射線障害予防及び／又は治療剤
JPH11269091A (ja) * 1998-03-19 1999-10-05 Snow Brand Milk Prod Co Ltd 敗血症予防及び／又は治療剤
CN1352087A (zh) * 2000-11-02 2002-06-05 上海博德基因开发有限公司 一种新的多肽——人糖蛋白42和编码这种多肽的多核苷酸
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
CN100417412C (zh) * 2003-03-28 2008-09-10 威海赛洛金药业有限公司 促肝细胞生长素注射液及制备方法和应用
CA2537246A1 (en) * 2003-09-03 2005-03-17 Kringle Pharma Inc. Skin ulcer preventive or curative agent containing human recombinant hgf
RU2520817C2 (ru) * 2006-01-25 2014-06-27 Октафарма Аг Очистка и применение фактора, способствующего заживлению ран
WO2008136183A1 (ja) * 2007-04-28 2008-11-13 Applied Cell Biotechnologies, Inc. 皮膚または歯肉の軟組織の欠損を補修するための組成物，及び自己線維芽細胞の培養方法
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
JP5579164B2 (ja) * 2008-04-09 2014-08-27 ビロメッド カンパニー， リミテッド 凍結乾燥ｄｎａ製剤、組成物、及び凍結乾燥ｄｎａ製剤を製造する方法
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
CN106456695B (zh) * 2014-04-28 2019-11-12 卫材R&D管理有限公司 Hgf的冻干配制品
WO2016039163A1 (ja) 2014-09-10 2016-03-17 クリングルファーマ株式会社 神経疾患の治療に適したｈｇｆ製剤
KR102275262B1 (ko) 2016-03-17 2021-07-12 에자이 알앤드디 매니지먼트 가부시키가이샤 활성 간세포 성장 인자(hgf)를 생성하는 방법
KR20210027493A (ko) 2018-07-19 2021-03-10 주식회사 헬릭스미스 네이키드 dna 유전자 요법을 위한 동결 건조된 약제학적 조성물
EP4574211A3 (de) 2021-05-14 2025-09-10 Claris Biotherapeutics, Inc. Zusammensetzungen von wachstumsfaktor zur behandlung von augenerkrankungen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58148826A (ja) * 1982-02-26 1983-09-05 Mochida Pharmaceut Co Ltd 糖蛋白質および腫瘍治療剤
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
DE3643182A1 (de) * 1986-12-18 1988-06-30 Behringwerke Ag Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4
JPS6410998A (en) * 1986-12-22 1989-01-13 Green Cross Corp Tumor cell inhibitory factor
JPS63243032A (ja) * 1987-03-27 1988-10-07 Green Cross Corp:The トロンビンの加熱処理方法
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JPH0741891B2 (ja) * 1987-08-26 1995-05-10 凸版印刷株式会社 容器素材成形装置
FI80741C (fi) * 1987-10-29 1990-07-10 Laennen Tehtaat Oy Modifierat papper.
DE69131069T2 (de) * 1990-07-13 1999-07-15 Snow Brand Milk Products Co., Ltd., Sapporo, Hokkaido Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung

Also Published As

Publication number Publication date
AU5177490A (en) 1990-10-09
HU212513B (en) 1996-07-29
EP0462277A4 (en) 1992-08-12
IE900863L (en) 1990-09-10
NO913546D0 (no) 1991-09-09
CA2049017A1 (en) 1990-09-11
HU211229A9 (en) 1995-11-28
RU95110767A (ru) 1997-06-10
EP0462277B1 (de) 1995-06-07
ES2075199T3 (es) 1995-10-01
FI102681B1 (fi) 1999-01-29
KR920701256A (ko) 1992-08-11
US5587359A (en) 1996-12-24
RU2113480C1 (ru) 1998-06-20
US6333309B1 (en) 2001-12-25
KR960009054B1 (ko) 1996-07-10
DE69019962D1 (de) 1995-07-13
NO180796C (no) 1997-06-25
JPH0768272B1 (de) 1995-07-26
HUT58797A (en) 1992-03-30
AU629314B2 (en) 1992-10-01
FI914234A0 (fi) 1991-09-09
NZ232813A (en) 1992-08-26
NO180796B (no) 1997-03-17
WO1990010651A1 (en) 1990-09-20
HU902330D0 (en) 1991-12-30
EP0462277A1 (de) 1991-12-27
IE64005B1 (en) 1995-06-28
NO913546L (no) 1991-11-11
DE69019962T2 (de) 1995-11-23
JPH0768272B2 (ja) 1995-07-26
DK0462277T3 (da) 1995-10-30
CA2049017C (en) 1998-10-27
FI102681B (fi) 1999-01-29

Similar Documents

Publication Publication Date Title
ATE123498T1 (de) Glykoprotein menschlichen ursprungs, physiologisch aktiver faktor, der es enthält und heilmittel daraus.
HU9201712D0 (en) A mammalian cytokine, il-11
MX9101913A (es) Derivados de quinazolinas para potenciar la actividad antitumoral
MY102505A (en) Novel osteoinductive factors.
IL88208A0 (en) Acylated uridine and cytidine and uses thereof
FI874819A7 (fi) Ihmisen yhdistelmä-endoteelisolun kasvutekijä.
ATE214610T1 (de) Neuartige pharmazeutische verwendungen von krill- enzymen
ES2055713T3 (es) Antibioticos con actividad antifungica.
DE69007744D1 (de) Verwendung von Interleukin 2 zur Behandlung von Leukämien.
ATE74272T1 (de) Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
IT1180161B (it) Procedimento e prodotti per la rivelazione del virus della leucemia delle cellule umane t.
IT1307724B1 (it) Fibra di ceramica, metallo o carbonio rivestita e procedimento diproduzione
CA2094275A1 (en) Methods and compositions for the treatment of cell proliferation disorders
FI922770A0 (fi) Bcrf1-proteinerna som inhibitorer av y-interferon.
DE59101214D1 (de) Verwendung der Ascorbinsäure zur Zubereitung von Arzneimitteln zur Anwendung im Genitalbereich.
IT218609Z2 (it) Supporto gonfiabile del busto e di altre parti del corpo umano.
ES2019025A6 (es) Procedimiento para preparar una composicion farmaceutica liquida de desmopresina.
DE3767175D1 (de) Therapeutische zusammenstellungen auf basis von 3-alkoxyflavonen und derivate von 3-alkoxyflavonen.
DE3869789D1 (de) Behandlung von einigen leukaemien mit einer zusammensetzung von interferon-gamma und interferon-alpha.
IT8622051A1 (it) Composizioni farmaceutiche ad attivita' cicatrizzante
ITPT910020A1 (it) Procedimento per eliminare i ganci e gli attacchi coronali nelle protesi dentali parziali mobili e materiali per la realizzazione del procedimento.
AU103662S (en) Trousers
AU95041S (en) Leg guard strap attachment for cricket pad
ATE73346T1 (de) Verwendung von interferon-beta und interleukin-2 in der kombinationstherapie und zusammensetzungen dazu.

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
EELA Cancelled due to lapse of time